🔴 Biomea Fusion is trading 20.6% down in after-hours trading with Phase I results call scheduled

Biomea Fusion is trading 20.6% down at $1.00 after the October 13 regular-session close; no verified company-specific explanation for the after-hours move was found.

• The company scheduled a 4:30 p.m. ET call to discuss Phase I results for its oral GLP-1 candidate BMF-650; available sources do not establish what the results showed.
• Biotech-sector weakness during the regular session and mixed broader markets do not establish a cause.